ABSTRACT
Objective To investigate the association between SARS-CoV-2 vaccination and myocarditis death
Design Population based comparative mortality study
Setting Japan
Participants Vaccinated population was 99 834 543 individuals aged 12 years and older who have been received SARS-CoV-2 vaccine once or twice by 14 February 2022. Reference population was defined persons aged 10 years and older from 2017 to 2019.
Main outcome measures The primary outcome was myocarditis death, defined as the case with “myocarditis” for cause of death and with onset 28 days or less after vaccination disclosed on 5 August 2022. Myocarditis mortality rate ratio (MMRR) of the SARS-CoV-2 vaccinated to the reference population by 10-year age group and standardised mortality ratio (SMR) were calculated. Mortality odds ratios (MORs) by 10-year age group were also calculated for supplementary analysis. Healthy vaccine effect-adjusted MMRRs (adMMRRs) or adjusted SMR (adSMR) were calculated by dividing MMRRs or SMR by 0.24 respectively.
Results Number of myocarditis death which met the inclusion criteria were 38 cases. MMRR (95% confidence interval) was 4.03 (0.77 to 13.60) in 20s, 6.69 (2.24 to 16.71) in 30s, 3.89 (1.48 to 8.64) in 40s, respectively. SMR of myocarditis was 2.01 (1.44 to 2.80) for overall vaccinated population, 1.65 (1.07 to 2.55) for those 60 years or older. Estimated adMMRRs and adSMR were about 4 times higher than the MMRRs and SMR. Pooled MOR for myocarditis were 205.60 (133.52 to 311.94).
Conclusion SARS-CoV-2 vaccination was associated with higher risk of myocarditis death, not only in young adults but also in all age groups including the elderly. Considering healthy vaccinee effect, the risk may be 4 times or higher than the apparent risk of myocarditis death. Underreporting should also be considered. Based on this study, risk of myocarditis following SARS-CoV-2 vaccination may be more serious than that reported previously.
ALREADY KNOWN ON THIS TOPIC There are many epidemiological studies showing increased myocarditis incidence after SARS-CoV-2 vaccination. There are also some case reports of fulminant myocarditis after receiving SARS-CoV-2 vaccine. However, no epidemiological studies focusing the association between vaccination and myocarditis death.
WHAT THIS STUDY ADDS Myocarditis mortality rate ratios (MMRRs) and their 95% confidence intervals (95% CIs) after receiving SARS-CoV-2 vaccine compared with that in the reference population (previous 3 years) were significantly higher not only in young adults (highest in the 30s with MMRR of 6.69) but also in the elderly. Standardised mortality ratio (SMR) for myocarditis was 1.65 (1.07 to 2.55) for those 60 years or older and 2.01 (1.44 to 2.80) in overall age. The risk of myocarditis mortality in the SARS-CoV-2 vaccinated population may be 4 times or higher than the apparent MMRRs considering healthy vaccinee effect. Unreported post-vaccination deaths should also be considered as suggested by the extremely high myocarditis mortality odds ratio (205.60; 133.52 to 311.94).
Competing Interest Statement
RH wrote a book entitled "Drugs to avoid, and infectious diseases including COVID-19" published on 1 December 2020.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
https://www.kantei.go.jp/jp/headline/kansensho/vaccine.html https://www.kantei.go.jp/jp/content/vaccination_data5.pdf https://www.mhlw.go.jp/content/10601000/000961882.pdf https://www.mhlw.go.jp/content/10601000/000961526.pdf https://www.mhlw.go.jp/content/10601000/000961527.pdf https://www.e-stat.go.jp/en/stat- search/files?page=1&layout=datalist&toukei=00200524&tstat=000000090001&cycle=7&year=20170&month=0&tclass1=000001011679&result_back=1&tclass2val=0 https://www.e-stat.go.jp/en/stat- search/files?page=1&layout=datalist&toukei=00200524&tstat=000000090001&cycle=7&year=20180&month=0&tclass1=000001011679&result_back=1&tclass2val=0 https://www.e-stat.go.jp/en/stat- search/files?page=1&layout=datalist&toukei=00200524&tstat=000000090001&cycle=7&year=20190&month=0&tclass1=000001011679&result_back=1&tclass2val=0 https://www.e-stat.go.jp/en/stat- search/files?page=1&layout=datalist&toukei=00450011&tstat=000001028897&cycle=7&year=20170&month=0&tclass1=000001053058&tclass2=000001053061&tclass3=000001053065&result_back=1&tclass4val=0 https://www.e-stat.go.jp/en/stat- search/files?page=1&layout=datalist&toukei=00450011&tstat=000001028897&cycle=7&year=20180&month=0&tclass1=000001053058&tclass2=000001053061&tclass3=000001053065&result_back=1&tclass4val=0 https://www.e-stat.go.jp/en/stat- search/files?page=1&layout=datalist&toukei=00450011&tstat=000001028897&cycle=7&year=20190&month=0&tclass1=000001053058&tclass2=000001053061&tclass3=000001053065&result_back=1&tclass4val=0 https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/datasets/deathsbyvaccinationstatusengland https://www.mhlw.go.jp/content/10601000/000972982.pdf https://github.com/owid/covid-19-data/tree/master/public/data Available at:https://www.niid.go.jp/niid/ja/2019-ncov/2484-idsc/10984-covid19-75.html
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
COMPETING INTERESTS: All authors have completed the ICMJE uniform disclose form available at https://www.icmje.org/disclosure-of-interest/, RH wrote a book entitled “Drugs to avoid, and infectious diseases including COVID-19” published on 1 December 2020.
FUNDING This survey does not receive any financial support from businesses or public institutions.
ETHICAL APPROVAL This study was conducted based only on data disclosed by the Japanese government. Japanese law and guidelines do not require an ethical approval for such research.
DISCLAIMER The content is the personal view of the author and is not related to the official view of the authors’ organization.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
